

Shweta Urva

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4158535/publications.pdf>

Version: 2024-02-01

9
papers

1,451
citations

1039406

9
h-index

1473754

9
g-index

9
all docs

9
docs citations

9
times ranked

928
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. <i>Lancet, The</i> , 2018, 392, 2180-2193.	6.3	528
2	LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. <i>Molecular Metabolism</i> , 2018, 18, 3-14.	3.0	400
3	Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. <i>JCI Insight</i> , 2020, 5, .	2.3	177
4	Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 938-946.	2.2	126
5	Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 418-429.	5.5	95
6	The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (<sc>GLP</sc>-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective <sc>long-acting GLP</sc>-1 receptor agonists. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1886-1891.	2.2	53
7	A phase 1 multiple-ascending dose study of tirzepatide in <sc>Japanese</sc> participants with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 239-246.	2.2	29
8	Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1049-1059.	1.6	27
9	Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide. <i>Clinical Pharmacokinetics</i> , 2022, 61, 1057-1067.	1.6	16